Venus Remedies share news and announcements
NSE: VENUSREMBSE: 526953Pharmaceuticals & BiotechnologySmall Cap
Last close ₹1,404.30down ₹37.20 (2.58%)BSE ₹1,396.30
Share price at the NSE close on 23 Oct 2026. Previous close ₹1,441.50.
52-week range of traded prices to 23 Oct 2026
₹432.10Low, 31 Oct 2025₹2,044.30High, 29 Jun 2026
- Under NSE's long-term additional surveillance, stage IV, on the list for 23 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Delivery only: shares bought must be paid for in full, with no selling on the same day.
- Next results date: the board meets on 26 Oct 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹1,877 Cr1,337th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 20 Jul 2026
- 16.2
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 26 May 2026
- 2.8
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.71%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 20 Jul 2026
- 19.0%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 20 Jul 2026
- 21.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 26 May 2026
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day.
- 52,800
Venus Remedies board meetings
168 filed, newest first. Page 1 of 4.
Oct 2026
Jul 2026
May 2026
26 May · Board meeting
Jan 2026
19 Jan · Board meeting
Not held on this date
Oct 2025
Aug 2025
1 Aug · Board meeting
Jul 2025
8 Jul · Board meeting
Jun 2025
May 2025
26 May · Board meeting
Feb 2025
4 Feb · Board meeting
Jan 2025
Oct 2024
29 Oct · Board meeting
Aug 2024
Jul 2024
May 2024
Feb 2024
14 Feb · Board meeting
14 Feb · Board meeting
Nov 2023
Oct 2023
Aug 2023
Jul 2023
14 Jul · Board meeting
May 2023
29 May · Board meeting
Jan 2023
Nov 2022
Jul 2022
May 2022
Jan 2022
31 Jan · Board meeting
Dec 2021
Oct 2021
30 Oct · Board meeting
Aug 2021
12 Aug · Board meeting
May 2021
31 May · Board meeting
Feb 2021
23 Feb · Board meeting